Unit:
Κατεύθυνση Παθολογία της ΚύησηςLibrary of the School of Health Sciences
Author:
Chondrakis Ioannis
Supervisors info:
Σοφία Καλανταρίδου, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ , (Επιβλέπουσα)
Παπαντωνίου Νικόλαος, Ομότιμος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Βραχνής Νικόλαος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Προεκλαμψία και καρδιαγγειακή νόσος. Ο ρόλος των στατινών στην υποστροφή της νόσου
Translated title:
Preeclampsia and cardiovascular disease.The role of statins in the regression of the disease
Summary:
Introduction: Preeclampsia is a major cause of maternal mortality and morbidity, premature birth, perinatal death and intrauterine growth restriction, as well as abnormal neonatal development. Statins display pleiotropic actions in various mechanisms related to the pathophysiology of preeclampsia and are therefore used empirically in the management of preeclampsia.
Aims & Objectives: The purpose of the present study is to provide a complete recording of new data on the role of statins in the regression of preeclampsia and cardiovascular disease during pregnancy.
Methodology: A review of articles in the existing bibliography was carried out for the completion of the present study. Online searches were carried out in the PubMed, Embase, Cinahl and Google scholar databases, from April 1 to May 30, 2019. Our search resulted in 90 articles. 70 of these were considered eligible sources from the title and abstract presented for general information extraction, while 10 were selected for inclusion in the literature review, and the articles were rejected
Results: Statins decreased sFlt-1 secretion by primary endothelial cells, cytotrophoblastic cells, and placental and serum implants and increased sENG secretion by endothelial cells. They also increase the secretion of soluble endoglin by endothelial cells (but do not alter its secretion by placental implants) and increase the expression of the antioxidant and cytoprotective enzyme, heme oxygenase 1. In addition, they reduce endothelial dysfunction and leukocyte adhesion to endothelial cells and increased endothelial cell migration and invasion. Finally, they appear to stabilize blood pressure, proteinuria and serum uric acid levels. There are also no differences in the incidence of congenital anomalies or other serious adverse reactions. The use of statins reduces the concentrations of maternal cholesterol but the concentrations of cholesterol in the umbilical cord and the birth weight are not affected.
Conclusions: Administration of statins (pravastatin, simvastatin etc) at a daily dose of 5-10 mg during pregnancy may be a good option for the prevention and treatment of preeclampsia in women and does not affect fetal development. A larger number of clinical trials are needed.
Main subject category:
Health Sciences
Keywords:
Preeclampsia, Cardiovascular disease, Pregnancy, Statins, Recurrence, Contraindications
Number of references:
126
